High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

BMC Cancer

Linxiang Luo¹  Cong Li²  Haifeng Yu²  Haiyan Yang²  Shuailing Peng²  Shuiyun Han²  Tao Lei²  Xi Chen²  Haiying Kong³  Xiaowu Dong⁴  Na Guo⁵  Meijuan Wu⁵ 

[1] Department of Hematology, Zhejiang Quhua Hospital, Quhua, China;Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China;Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China;Department of Pharmacy, Zhejiang Medical and Health Group Hangzhou Hospital (Hangzhou Hanggang Hospital), Hangzhou, China;Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China;Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China;Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 Banshan East Road, Hangzhou, China;

关键词: Hodgkin lymphoma;    PD-1 inhibitor;    PD-L1 inhibitor;    PD-L2;    Molecular phenotype;    Tumor microenvironment;   

DOI  :  10.1186/s12885-021-09028-4

来源: Springer

【 授权许可】

CC BY